ERBB2 and breast carcinoma: Single agent palbociclib demonstrated activity in genetically engineered mouse models of a HER2-positive, Rb-proficient breast cancer; however, combinations of palbociclib with carboplatin resulted in lower cytotoxicity than single-agent chemotherapy [39].